NICE discount doesn't save Pixuvri from rejection; Antares nabs FDA nod for self-injected RA drug;

@FiercePharma: Biggest new news Monday: Irate Teva reps vow to strike against Israeli job cuts. Story | Follow @FiercePharma

@CarlyHFierce: Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. ICYMI yesterday | Follow @CarlyHFierce

> The U.K.'s cost-effectiveness watchdog didn't budge on its rejection of Cell Therapeutics' ($CTIC) lymphoma drug Pixuvri, despite the company's offer of a discount. Report

> Antares Pharma won FDA approval for its drug Otrexup, a once-a-week, self-injected version of the standard oral treatment for rheumatoid arthritis and psoriasis, methotrexate. Report (sub. req.)

> The British pharma market is expected to hit $31.7 billion by 2010, GlobalData says, with good access to healthcare and a growing disease burden fueling growth. Report

> Cancer cases cost Europe €126 billion in 2009, including a €51 billion outlay on healthcare expenses; spending varied widely, from €16 per citizen in Bulgaria to €184 per capita in Luxembourg. Report

> A Madrid court yesterday heard Spain's first lawsuit against Germany's Grunenthal, which made the morning sickness drug thalidomide that caused birth defects in many babies. Report

> Of the 66 drugmakers that have received warning letters from the FDA since 2010, 12% were Indian companies, the Daily Mail found. Report

> Amid shortages of its usual execution drugs, Florida plans to execute a death-row inmate using the drug midazolam hydrochloride, despite worries that it may not work as promised. Report

Medical Device News

@FierceMedDev: Natera expands prenatal test amid global push. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Who are this year's FMD Fierce 15 winners? Find out here | Follow @MarkHFierce

@MichaelGFierce: Critical Diagnostics launches point-of-care cardiac disease test. Item | Follow @MichaelGFierce

> Covidien PAD treatments show promise in two trials. Article

> J&J's med tech biz falters amid weak sales, M&A rumors. Story

> Senate debt, government funding compromise avoids addressing device tax repeal. Report

Biotech News

@FierceBiotech: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline. More | Follow @FierceBiotech

@JohnCFierce: PhIII blunders that have helped define companies, for better or worse. The top Phase III R&D setbacks of 2013 | Follow @JohnCFierce

@DamianFierce: If Myriad was a big dog in a small park in its fight with Ambry and Gene by Gene, Quest is a dog colossus. | Follow @DamianFierce

> Billionaire-backed immatics bags $46M to wrap cancer vaccine PhIII. Story

> JDRF, PureTech launch diabetes startup initiative. More

> AstraZeneca buys Spirogen in $440M deal, inks pact in armed antibody double-play. Story

> Aerie Pharma craves $84.5M in amped-up offering as IPOs pour in. More

> Sanofi plots more cuts at slow-footed French R&D shop. Article

Biotech Research News

@EmilyMFierce: Parkinson's may take two forms, one more toxic than the other. More | Follow @EmilyMFierce

> Vegetable-based compound protects against side effects of radiation therapy. Story

> Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact. Report

> Compound halts neurodegeneration in mice. More

> Gene therapy plus stem cells quickens wound healing. Article

> Boston University, MRC Technology developing anti-inflammatory antibody. Item

Pharma Manufacturing News

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article | Follow @EricPFierce

> U.S. awards special status to fired Novartis workers. Report

> Israeli unions threaten strikes over Teva job cuts. Item

> FDA closes out inspection on Ranbaxy New Jersey plant. More

> SAFC adds biologics capabilities at 2 plants. News

> Roche expanding biologics production in 3 countries. Story

And Finally... Can grandma's knees predict the weather? Scientists think they might. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.